Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing

Oct 08 2020

• By Joseph Haas

Indianapolis - Circa April 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals IV - Image

Related Content

How Much Should Governments Pay For COVID-19 Monoclonal Antibody Therapies?

Oct 08 2020

Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire

Oct 05 2020

Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US

Jun 30 2020

Regeneron and Roche Await Data On Potential COVID-19 Blockbuster

Sep 03 2020

Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy

Sep 16 2020

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Sep 18 2020

Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Sep 30 2020

Related Companies

Eli Lilly and Company

Regeneron Pharmaceuticals, Inc.

Roche Holding AG

Gilead Sciences, Inc.

Additional Topics

United States Manufacturing Drug Approval Standards Drug Review Regulation Clinical Trials Coronavirus COVID-19 BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window